Table VII.

Objective characteristics of examiner-rated assessments of the global functioning of participants who underwent positron emission tomography (PET) of the brain following the intravenous administration of 444 MBq (12 mCi) 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA)

Age in years	Male sexa	CGISI	CGIGI	CGIEI	CGIRGE	MMSE	SSC
Range of scores	(1, 0)	(1, 7)	(1, 7)	(1, 16)	(1, 7)	(0, 30)	(0, 55)
22	1	.	.	.	.	.	.
23	1	.	.	.	.	.	.
23	0	.	.	.	.	.	.
31	0	.	.	.	.	.	.
45	1	1	4	13	4	28	0
47	1	.	.	.	.	29	0
49	1	6	4	13	4	28	0
51	1	6	4	13	4	29	0
53	1	6	4	13	4	24	4
56	0	4	4	13	4	25	0

Clinical Global Impressions: CGISI = Severity of Illness, CGIGI = Global Improvement, CGIEI = Efficacy Index (Guy, 1976); CGIRGE = Clinical Global Improvement Rater Global Evaluation (Pato and Pato, 1991); MMSE = Mini-Mental State Examination (Blacker, 2009; Folstein et al., 1975; Marder, 1995); SSC = Serotonin Syndrome Checklist (Brasić et al., 1998); Period (.) = missing data.

^a0 = absent; 1 = present.